inclusion criteria: written documentation of sars-cov-2 infection confirmed by a validated test. presence of greater than or equal to ≥1 of the following covid-19-related symptoms indicating mild disease: fever (temperature ≥100.4), anosmia (loss of taste or smell), cough, sore throat, gastrointestinal complaints (e.g. nausea, vomiting, or diarrhea), chills, congestion, or runny nose, headaches, muscle or body aches, fatigue, or asymptomatic patients who have tested positive for covid-19 via a validated test within the past 4 days. if symptomatic, symptom onset less than or equal to ≤ 8 days. for female participants of childbearing potential, a negative urine (or serum) pregnancy test. for female participants of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until greater than or equal to ≥30 days after the final dose of study therapy. note: a female subject is considered to be of childbearing potential unless she has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure (with serum estradiol and follicle-stimulating hormone [fsh] levels within the institutional laboratory postmenopausal range and a negative serum or urine beta human chorionic gonadotropin [βhcg]); or is menopausal (age ≥50 years with amenorrhea for ≥6 months). for male participants who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥30 days after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥90 days after administration of the final dose of study therapy. note: a male subject is considered able to father a child unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy. willingness and ability of the participant to ingest study drug capsules. willingness of the participant to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, study procedures, and study restrictions. evidence of a personally signed informed consent indicating that the participant is aware of the nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.

inclusion criteria: written documentation of sars-cov-2 infection confirmed by a validated test. presence of greater than or equal to ≥1 of the following covid-19-related symptoms indicating mild disease: fever (temperature ≥100.4), anosmia (loss of taste or smell), cough, sore throat, gastrointestinal complaints (e.g. nausea, vomiting, or diarrhea), chills, congestion, or runny nose, headaches, muscle or body aches, fatigue, or asymptomatic patients who have tested positive for covid-19 via a validated test within the past 4 days. if symptomatic, symptom onset less than or equal to ≤ 8 days. for female participants of childbearing potential, a negative urine (or serum) pregnancy test. for female participants of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until greater than or equal to ≥30 days after the final dose of study therapy. note: a female subject is considered to be of childbearing potential unless she has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure (with serum estradiol and follicle-stimulating hormone [fsh] levels within the institutional laboratory postmenopausal range and a negative serum or urine beta human chorionic gonadotropin [βhcg]); or is menopausal (age ≥50 years with amenorrhea for ≥6 months). for male participants who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥30 days after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥90 days after administration of the final dose of study therapy. note: a male subject is considered able to father a child unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy. willingness and ability of the participant to ingest study drug capsules. willingness of the participant to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, study procedures, and study restrictions. evidence of a personally signed informed consent indicating that the participant is aware of the nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.

inclusion criteria: 1. written documentation of sars-cov-2 infection confirmed by a validated test. 2. presence of greater than or equal to ≥1 of the following covid-19-related symptoms indicating mild disease: fever (temperature ≥100.4), anosmia (loss of taste or smell), cough, sore throat, gastrointestinal complaints (e.g. nausea, vomiting, or diarrhea), chills, congestion, or runny nose, headaches, muscle or body aches, fatigue, or asymptomatic patients who have tested positive for covid-19 via a validated test within the past 4 days. 3. if symptomatic, symptom onset less than or equal to ≤ 8 days. 4. for female participants of childbearing potential, a negative urine (or serum) pregnancy test. 5. for female participants of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until greater than or equal to ≥30 days after the final dose of study therapy. note: a female subject is considered to be of childbearing potential unless she has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure (with serum estradiol and follicle-stimulating hormone [fsh] levels within the institutional laboratory postmenopausal range and a negative serum or urine beta human chorionic gonadotropin [βhcg]); or is menopausal (age ≥50 years with amenorrhea for ≥6 months). 6. for male participants who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥30 days after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥90 days after administration of the final dose of study therapy. note: a male subject is considered able to father a child unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy. 7. willingness and ability of the participant to ingest study drug capsules. 8. willingness of the participant to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, study procedures, and study restrictions. 9. evidence of a personally signed informed consent indicating that the participant is aware of the nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.

inclusion criteria: 1. written documentation of sars-cov-2 infection confirmed by a validated test. 2. presence of greater than or equal to ≥1 of the following covid-19-related symptoms indicating mild disease: fever (temperature ≥100.4), anosmia (loss of taste or smell), cough, sore throat, gastrointestinal complaints (e.g. nausea, vomiting, or diarrhea), chills, congestion, or runny nose, headaches, muscle or body aches, fatigue, or asymptomatic patients who have tested positive for covid-19 via a validated test within the past 4 days. 3. if symptomatic, symptom onset less than or equal to ≤ 8 days. 4. for female participants of childbearing potential, a negative urine (or serum) pregnancy test. 5. for female participants of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until greater than or equal to ≥30 days after the final dose of study therapy. note: a female subject is considered to be of childbearing potential unless she has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure (with serum estradiol and follicle-stimulating hormone [fsh] levels within the institutional laboratory postmenopausal range and a negative serum or urine beta human chorionic gonadotropin [βhcg]); or is menopausal (age ≥50 years with amenorrhea for ≥6 months). 6. for male participants who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥30 days after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥90 days after administration of the final dose of study therapy. note: a male subject is considered able to father a child unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy. 7. willingness and ability of the participant to ingest study drug capsules. 8. willingness of the participant to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, study procedures, and study restrictions. 9. evidence of a personally signed informed consent indicating that the participant is aware of the nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.

inclusion criteria: 1. presence of sars-cov-2 infection confirmed by polymerase chain reaction (rt-pcr) test. 2. presence of great than or equal to ≥1 of the following covid-19-related symptoms indicating mild disease: fever (temperature ≥100.4), anosmia, cough, sore throat, gastrointestinal complaints (e.g. vomiting, or diarrhea) 3. symptom onset less than or equal to ≤ 4 days. 4. for female participants of childbearing potential, a negative urine (or serum) pregnancy test. 5. for female participants of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until greater than or equal to ≥30 days after the final dose of study therapy. note: a female subject is considered to be of childbearing potential unless she has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure (with serum estradiol and follicle-stimulating hormone [fsh] levels within the institutional laboratory postmenopausal range and a negative serum or urine beta human chorionic gonadotropin [βhcg]); or is menopausal (age ≥50 years with amenorrhea for ≥6 months). 6. for male participants who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥30 days after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥90 days after administration of the final dose of study therapy. note: a male subject is considered able to father a child unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy. 7. willingness and ability of the participant to ingest study drug capsules. 8. willingness of the participant to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, study procedures, and study restrictions. 9. evidence of a personally signed informed consent indicating that the participant is aware of the nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.

inclusion criteria: 1. presence of sars-cov-2 infection confirmed by polymerase chain reaction (rt-pcr) test. 2. presence of great than or equal to ≥1 of the following covid-19-related symptoms indicating mild disease: fever (temperature ≥100.4), anosmia, cough, sore throat, gastrointestinal complaints (e.g. vomiting, or diarrhea) 3. symptom onset less than or equal to ≤ 4 days. 4. for female participants of childbearing potential, a negative urine (or serum) pregnancy test. 5. for female participants of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until greater than or equal to ≥30 days after the final dose of study therapy. note: a female subject is considered to be of childbearing potential unless she has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure (with serum estradiol and follicle-stimulating hormone [fsh] levels within the institutional laboratory postmenopausal range and a negative serum or urine beta human chorionic gonadotropin [βhcg]); or is menopausal (age ≥50 years with amenorrhea for ≥6 months). 6. for male participants who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥30 days after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥90 days after administration of the final dose of study therapy. note: a male subject is considered able to father a child unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy. 7. willingness and ability of the participant to ingest study drug capsules. 8. willingness of the participant to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, study procedures, and study restrictions. 9. evidence of a personally signed informed consent indicating that the participant is aware of the nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.